Ramona Rudalska

Ramona Rudalska

Auto-generated profile, based on publicly available information

Ramona Rudalska

Department of Medical Oncology and Pneumology University Hospital Tübingen Tübingen Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
RRRamona Rudalska
Ramona Rudalska
JHJule Harbig
Jule Harbig
MSMarteinn T. Snaebjornsson
Marteinn T. Snaebjornsson
SKSabrina Klotz
Sabrina Klotz
SZStefan Zwirner
Stefan Zwirner
DDDaniel Dauch
Daniel Dauch

20 January 2025 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
MSMarteinn T. Snaebjornsson
Marteinn T. Snaebjornsson
PBPhilipp Biechl
Philipp Biechl
DKDaria Komkova
Daria Komkova
FRFlorian Röhrig
Florian Röhrig
LSLisa Schlicker
Lisa Schlicker
ASAlmut SChulze
Almut SChulze
Increased glycolytic flux is a hallmark of cancer; however, an increasing body of evidence indicates that glycolytic ATP production may be dispensable in cancer, as metabolic plasticity allows cancer cells to readily adapt to disruption of glycolysis by increasing ATP production via oxidative phosphorylation. Using functional genomic screening, we show here that liver cancer cells show a unique sensitivity toward aldolase A (ALDOA) depletion. Targeting glycolysis by disrupting the catalytic activity of ALDOA led to severe energy stress and cell cycle arrest in murine and human hepatocellular carcinoma cell lines. With a combination of metabolic flux analysis, metabolomics, stable-isotope tracing and mathematical modelling, we demonstrate that inhibiting ALDOA induced a state of imbalanced glycolysis in which the investment phase outpaced the payoff phase. Targeting ALDOA effectively converted glycolysis from an energy producing into an energy-consuming process. Moreover, we found that depletion of ALDOA extended survival and reduced cancer cell proliferation in an animal model of hepatocellular carcinoma. Thus, our findings indicate that induction of imbalanced glycolysis by targeting ALDOA presents a unique opportunity to overcome the inherent metabolic plasticity of cancer cells.

16 January 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
RRRamona Rudalska
Ramona Rudalska
JHJule Harbig
Jule Harbig
MFMichael Forster
Michael Forster
PWPascal Woelffing
Pascal Woelffing
AEAylin Esposito
Aylin Esposito
DDDaniel Dauch
Daniel Dauch
Colorectal cancer (CRC) constitutes the second leading cause of cancer-related death worldwide and advanced CRCs are resistant to targeted therapies, chemotherapies and immunotherapies. p38α (Mapk14) has been suggested as a therapeutic target in CRC; however, available p38α inhibitors only allow for insufficient target inhibition. Here we describe a unique class of p38α inhibitors with ultralong target residence times (designated ULTR-p38i) that robustly inhibit p38α downstream signaling and induce distinct biological phenotypes. ULTR-p38i monotherapy triggers an uncontrolled mitotic entry by activating Cdc25 and simultaneously blocking Wee1. Consequently, CRC cells undergo mitotic catastrophe, resulting in apoptosis or senescence. ULTR-p38i exhibit high selectivity, good pharmaco-kinetic properties and no measurable toxicity with strong therapeutic effects in patient-derived CRC organoids and syngeneic CRC mouse models. Conceptually, our study suggests ultralong-target-residence-time kinase inhibitors as an alternative to covalent inhibitors, which, because of the lack of cysteine residues, cannot be generated for many kinase cancer targets.

23 July 2021 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
RRRamona Rudalska
Ramona Rudalska
LZLars Zender
Lars Zender
DDDaniel Dauch
Daniel Dauch
Summary: Metabolic alterations occur frequently in solid tumours, but metabolic cancer therapies are limited by the complexity and plasticity of metabolic networks. We could recently show that activation of the liver X receptor alpha (LXRα) and inhibition of a Raf-1-SCD1 protein complex induces an intracellular accumulation of saturated free fatty acids leading to lethal lipotoxicity in tumour cells and allows for an efficient treatment of liver carcinomas.

15 September 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
NSNico J. Seidler
Nico J. Seidler
MMMonica R. MacDonald
Monica R. MacDonald
AMAthina A. Moschopoulou
Athina A. Moschopoulou
SCSahba Cunningham
Sahba Cunningham
TWTess M. Weber
Tess M. Weber
DHDavid E. Heppner
David E. Heppner
Rendering kinase inhibitors selective is a strict requirement in drug development and remains a persistent challenge. To identify new routes to engineer selectivity, we have discovered a first‐in‐class p38δ‐isoform selective inhibitor reflecting 12 000‐fold selectivity improvement over currently available compounds and superior kinome targeting. X‐ray crystallographic characterization indicates that these molecules bind through noncanonical n–π–π stacking sandwich interactions enabled by structural remodeling of the P‐loop. Structural and functional analysis indicates that these selective inhibitors are self‐encapsulating agents due to direct steric clashing that occludes the binding site in a conformation reinforced by a hydrogen‐bonding network involving p38δ‐unique H30. This work reveals how inhibitor selectivity is achieved by deliberate remodeling of the drug binding site leveraging structural features outside the binding site commonly overlooked in structure‐guided design.